In melanoma, breast cancer, colon cancer, non-small cell lung cancer (NSCLC), prostate cancer, and other malignant tumors (24, 43, 45), combining the CD73 mAb with the PD-1 mAb has shown a more significant effect than these drugs alone. The gene discussed is PDCD1; the disease is breast carcinoma.